BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $16 from $45 and keeps an Outperform rating on the ...

Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

Neurogene (NASDAQ:NGNE – Get Free Report) had its target price lowered by equities researchers at BMO Capital Markets from $45.00 to $16.00 in a note issued to investors on Monday,Benzinga reports.

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and ...

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares. Last week, the company reported that NGN-401 had shown ...

Neurogene Inc. (NASDAQ:NGNE – Free Report) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Neurogene in a research note issued to investors on Tuesday ...

NEUROGENE ($NGNE) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue of $0 and ...

Neurogene Inc :* NEUROGENE INC - MODIFIE L'ACCORD AVEC BAKER BROS POUR AUGMENTER LE SEUIL DE NOMINATION - DÉPÔT AUPRÈS DE LA ...

Investing.com — Neurogene Inc. (NASDAQ: NGNE ), une entreprise pharmaceutique avec une capitalisation boursière de 163,48 millions $, a annoncé aujourd’hui une modification à un accord existant avec B ...

Investing.com — Lundi, BMO Capital Markets a ajusté ses perspectives sur Neurogene (NASDAQ: NGNE) en réduisant considérablement l’objectif de cours de la société de 45,00$ à 16,00$. Malgré ce changeme ...

2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...